Business
Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting
~ Two oral abstracts highlight positive findings from pivotal studies for the treatment of sebaceous hyperplasia and cutaneous non-genital warts with the
About this update from Pulse Biosciences, Inc
[{"type":"text","content":"\n~ Two oral abstracts highlight positive findings from pivotal studies for the treatment of sebaceous hyperplasia and cutaneous non-genital warts with the CellFX® System ~\n\n~ Two posters showcase favorable results of the CellFX System for the treatment of plantar warts and basal cell carcinoma ~\n\n HAYWARD, Calif.--(BUSINESS WIRE)--\nPulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinical results from studies spanning the Company’s dermatologic application portfolio will be presented at the American Society for Dermatologic Surgery (ASDS) virtual annual meeting on October 9-11, 2020. Positive study results generated using the Company’s innovative cellular-specific Nano-Pulse Stimulation mechanism performed with its CellFX System for the treatment of sebaceous hyperplasia lesions, cutaneous non-genital warts, plantar warts, and basal cell carcinoma will be presented in two oral presentations and two e-posters.\n\nThese newest published results from NPS clinical studies provide further evidence of the unique CellFX cellular mechanism of action for multiple applications across the lesion treatment spectrum. These recent findings were also the basis for the recently initiated multicenter clinical study to compare NPS technology to RF electrodessication in clearing sebaceous hyperplasia lesions. Treatment of the first study patient was previously announced by the Company on October 1, 2020.\n\n“The positive results being shared at this year’s ASDS meeting add to the growing body of evidence in support of using Nano-Pulse Stimulation technology delivered by the CellFX System to treat a broad range of dermatology applications for which targeted clearance of cellular lesions or structures is medically or cosmetically desirable,” said Darrin Uecker, President and CEO of Pulse Biosciences. “These data underscore our persistent dedication to providing dermatologists a highly differentiated non-thermal solution with vast opportunity.”\n\nHighlights from this meeting of leading dermatologic surgeons demonstrate:\n\n\nSuccessful use of lower NPS energy levels to maintain high levels of effectiveness in clearing sebaceous hyperplasia lesions with greatly improved cosmesis and high subject satisfaction\n\n\nFavorable clearance rate for w...